| 16.185 0.365 (2.31%) | 04-27 11:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.11 | 1-year : | 19.99 |
| Resists | First : | 16.36 | Second : | 17.12 |
| Pivot price | 16.37  |
|||
| Supports | First : | 15.14 | Second : | 12.59 |
| MAs | MA(5) : | 15.96 |
MA(20) : | 16.31 |
| MA(100) : | 16.88 |
MA(250) : | 15.1 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 17.1 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 18.91 | Low : | 10.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BLCO ] has closed above bottom band by 32.1%. Bollinger Bands are 14% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.89 - 16.01 | 16.01 - 16.09 |
| Low: | 15.46 - 15.58 | 15.58 - 15.67 |
| Close: | 15.66 - 15.85 | 15.85 - 15.99 |
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Sun, 26 Apr 2026
JP Morgan Maintains Bausch + Lomb (BLCO) Neutral Recommendation - MSN
Sun, 26 Apr 2026
Bausch + Lomb (BLCO) Q4 earnings: What to expect - MSN
Sun, 26 Apr 2026
Bausch + Lomb (BLCO) Status update Summary - Quartr
Sat, 25 Apr 2026
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Sat, 25 Apr 2026
Barclays Reaffirms Their Hold Rating on Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Thu, 23 Apr 2026
BLCO SEC Filings - Bausch + Lomb Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 356 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 87.5 (%) |
| Held by Institutions | 11.5 (%) |
| Shares Short | 3,610 (K) |
| Shares Short P.Month | 2,660 (K) |
| EPS | -1.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.2 |
| Profit Margin | -7.1 % |
| Operating Margin | 11.2 % |
| Return on Assets (ttm) | 0.8 % |
| Return on Equity (ttm) | -5.4 % |
| Qtrly Rev. Growth | 9.8 % |
| Gross Profit (p.s.) | 8.55 |
| Sales Per Share | 14.31 |
| EBITDA (p.s.) | 1.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 283 (M) |
| Levered Free Cash Flow | 141 (M) |
| PE Ratio | -15.8 |
| PEG Ratio | 0.8 |
| Price to Book value | 0.88 |
| Price to Sales | 1.12 |
| Price to Cash Flow | 20.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|